Create Free Account

By creating account you will get access to hot stocks & personalised emails

Neuren Pharmaceuticals Ltd

Healthcare AU NEU

19.18AUD
0.12(0.63%)

Last update at 2024-05-02T06:10:00Z

Day Range

18.9519.34
LowHigh

52 Week Range

10.0225.95
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 0.18M -7.79400M -9.19300M -10.81600M 3.07M
Minority interest - - - - -
Net income 2.37M -7.74500M -9.04000M -10.42300M 3.07M
Selling general administrative 3.44M 1.91M 1.76M 1.71M 2.07M
Selling and marketing expenses - - - - -
Gross profit 14.55M - - -9.36300M 7.89M
Reconciled depreciation 0.01000M 0.00800M 0.00600M 0.00400M 0.08M
Ebit -1.60600M -11.43800M -9.53200M -11.57500M 3.07M
Ebitda -1.59600M -11.43000M -9.52600M -11.57100M 3.15M
Depreciation and amortization 0.01000M 0.00800M 0.00600M 0.00400M 0.08M
Non operating income net other - - - - -
Operating income -1.60600M -11.43800M -9.53200M -11.57500M -8.25300M
Other operating expenses 16.16M 11.44M 9.53M 11.57M -
Interest expense 0.39M 3.64M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.39M 0.40M 0.15M 0.13M 2.96M
Net interest income 0.39M 0.04M 0.15M 0.39M 0.22M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.18100M -0.04900M -0.15300M -0.39300M 0.00000M
Total revenue 14.55M 0.04M 0.15M 0.39M 13.76M
Total operating expenses 16.16M 11.44M 9.53M 11.57M 8.25M
Cost of revenue - - - 9.86M 6.10M
Total other income expense net 1.79M 3.64M 0.34M 0.76M 11.33M
Discontinued operations - - - - -
Net income from continuing ops 0.18M -7.79400M -9.19300M -10.81600M 3.07M
Net income applicable to common shares 0.18M -7.79400M -9.19300M -10.81600M 3.07M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 247.97M 43.27M 40.06M 24.95M 14.41M
Intangible assets - - - - 0.00000M
Earning assets - - - - -
Other current assets 4.21M 1.98M 1.84M - 0.00000M
Total liab 42.76M 1.68M 0.80M 0.75M 0.56M
Total stockholder equity 205.21M 41.59M 39.25M 24.20M 13.85M
Deferred long term liab - - - - -
Other current liab 42.09M 1.42M 0.56M 0.59M 0.22M
Common stock 173.13M 167.74M 167.58M 145.57M 126.43M
Capital stock 173.13M 167.74M 167.58M 145.57M 126.43M
Retained earnings 38.39M -118.69300M -118.87700M -111.08300M -104.07600M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 17.09M 40.18M 36.78M 24.19M 13.84M
Cash and equivalents - 37.88M 29.87M 23.96M 13.02M
Total current liabilities 42.76M 1.68M 0.80M 0.75M 0.56M
Current deferred revenue - - - - -
Net debt -17.09400M -40.18000M -36.78300M -24.18800M -13.84400M
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - -10.68000M -9.44800M -10.28400M -8.50300M
Property plant equipment - 0.02M 0.01M 0.01000M 0.01000M
Total current assets 247.16M 43.25M 40.04M 24.94M 14.40M
Long term investments - - - - -
Net tangible assets - 41.59M 39.25M 24.20M 13.85M
Short term investments 211.44M - - 23.96M 13.02M
Net receivables 14.41M 1.09M 1.42M 0.76M 0.55M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.68M 0.26M 0.24M 0.17M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -6.30800M -7.45800M -9.44800M -10.28400M -8.50300M
Additional paid in capital - - - - -
Common stock total equity - - - 145.57M 126.43M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M - - - 0.01000M
Deferred long term asset charges - - - - -
Non current assets total 0.81M 0.02M 0.01M 0.01000M 0.01000M
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01900M -0.01000M -0.00600M -0.01200M -
Change to liabilities 0.34M -0.11400M 0.19M -1.41400M 0.39M
Total cashflows from investing activities -0.01900M -0.01000M -0.00600M -0.01200M -0.01200M
Net borrowings - - - - -
Total cash from financing activities -0.00200M 22.18M 19.14M 1.86M 11.71M
Change to operating activities - - - - -
Net income 2.37M -7.79400M -9.19300M -10.81600M 3.07M
Change in cash 3.40M 12.60M 10.34M -9.73000M 18.87M
Begin period cash flow 36.78M 24.19M 13.84M 23.58M 4.71M
End period cash flow 40.18M 36.78M 24.19M 13.85M 23.58M
Total cash from operating activities 2.38M -9.97000M -8.07800M -11.71900M 6.41M
Issuance of capital stock - 23.28M 20.22M 1.86M 11.73M
Depreciation 0.01000M 0.00800M 0.00600M 0.00400M 0.08M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.19M -2.50600M -0.20300M 0.39M -0.25000M
Sale purchase of stock -0.00200M -1.10600M -1.07500M - -0.01600M
Other cashflows from financing activities -0.01900M -0.01000M -0.00600M -0.01200M 6.41M
Change to netincome 2.87M 0.44M 1.12M 0.12M 3.12M
Capital expenditures 0.02M 0.01000M 0.00600M 0.01M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.23300M 0.82M -0.72500M -0.87900M -1.11300M
Stock based compensation - - - - -
Other non cash items -2.37500M 7.79M 9.19M 10.81M -3.15100M
Free cash flow 2.36M -9.98000M -8.08400M -11.73100M 6.41M

Fundamentals

  • Previous Close 19.06
  • Market Cap2492.36M
  • Volume191829
  • P/E Ratio15.98
  • Dividend Yield-%
  • EBITDA199.26M
  • Revenue TTM231.94M
  • Revenue Per Share TTM1.82
  • Gross Profit TTM 2.71M
  • Diluted EPS TTM1.20

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.63% 19.18 15.98 38.46 11.63 13.15 10.65 12.39
CSL
CSL Ltd		 0.90 0.33% 275.39 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.13 0.89% 14.80 748.00 21.01 8.47 28.69 8.21 177.65
MSB
Mesoblast Ltd		 -0.03 2.73% 1.07 - 769.23 116.88 1.12 126.11 -19.3368
CU6
Clarity Pharmaceuticals Ltd		 0.26 8.64% 3.27 - - 85.90 15.59 - -18.7407

Reports Covered

Stock Research & News

View All

Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Ltd

697 Burke Road, Camberwell, VIC, Australia, 3124

Key Executives

Name Title Year Born
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons) CEO, MD & Director NA
Ms. Lauren Frazer C.A. CFO & Company Sec. NA
Mr. Lawrence Glass Chief Science Officer NA
Mr. Gerry Zhao VP of Corp. Devel. NA
Dr. Liza A. Squires M.D. Chief Medical Officer NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA
Ms. Lauren Frazer C.A. CFO & Company Secretary NA
Mr. Lawrence Glass BA (Biology) Chief Science Officer NA
Mr. Gerry Zhao Vice President of Corporate Development NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.